Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Short Interest Falls 82.9%

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the target of a large decrease in short interest during the month of September. As of September 15th, there was short interest totaling 5,915 shares, a decrease of 82.9% from the August 31st total of 34,593 shares. Approximately 0.4% of the company’s shares are short sold. Based on an average daily volume of 38,250 shares, the short-interest ratio is presently 0.2 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Global X Genomics & Biotechnology ETF stock. Bank of America Corp DE increased its position in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 67.8% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 119,795 shares of the company’s stock after acquiring an additional 48,394 shares during the period. Bank of America Corp DE owned about 10.70% of Global X Genomics & Biotechnology ETF worth $5,240,000 at the end of the most recent reporting period. 56.95% of the stock is owned by hedge funds and other institutional investors.

Global X Genomics & Biotechnology ETF Trading Down 1.2%

Shares of GNOM stock traded down $0.84 during trading hours on Friday, reaching $69.41. The company’s stock had a trading volume of 2,685 shares, compared to its average volume of 18,194. Global X Genomics & Biotechnology ETF has a one year low of $37.25 and a one year high of $70.73. The stock has a market capitalization of $104.12 million, a P/E ratio of -29.66 and a beta of 1.19. The firm’s fifty day simple moving average is $61.21 and its 200 day simple moving average is $52.78.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.